No changes in PARP-1 expression profiles following olaparib or MC2050 treatments were detected, thus suggesting that in our AD model, the enzymatic activity of PARP-1 following inhibitor treatments is not directly correlated with its transcriptional regulation. Here, PARP1 is linked to Alzheimer disease.